Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4321 AL 4335

Resveratrol and Alzheimer's Disease: Mechanistic Insights

Ahmed T, Javed S, Javed S, Tariq A, Šamec D, Tejada S, Nabavi SF, Braidy N, Nabavi SM.

Mol Neurobiol. 2017 May;54(4):2622-2635. doi: 10.1007/s12035-016-9839-9. Epub 2016 Mar 19.

Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy

Hamel E, Royea J, Ongali B, Tong XK.

Cell Mol Neurobiol. 2016 Mar;36(2):219-32. doi: 10.1007/s10571-015-0285-4. Epub 2016 Mar 18.

Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease

Saavedra JM.

Cell Mol Neurobiol. 2016 Mar;36(2):259-79. doi: 10.1007/s10571-015-0327-y. Epub 2016 Mar 18.

The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target

Chu J, Praticò D.

Brain Res Bull. 2016 Sep;126(Pt 2):207-212. doi: 10.1016/j.brainresbull.2016.03.010. Epub 2016 Mar 19.

Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?

Bursavich MG, Harrison BA, Blain JF.

J Med Chem. 2016 Aug 25;59(16):7389-409. doi: 10.1021/acs.jmedchem.5b01960. Epub 2016 Apr 5.

Neurorestorative Role of Stem Cells in Alzheimer's Disease: Astrocyte Involvement

Choi SS, Lee SR, Lee HJ.

Curr Alzheimer Res. 2016;13(4):419-27. doi: 10.2174/156720501304160314162812.

Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors

Evin G.

BioDrugs. 2016 Jun;30(3):173-94. doi: 10.1007/s40259-016-0168-3.

Short-Term Effects of Rhythmic Sensory Stimulation in Alzheimer's Disease: An Exploratory Pilot Study

Clements-Cortes A, Ahonen H, Evans M, Freedman M, Bartel L.

J Alzheimers Dis. 2016 Mar 25;52(2):651-60. doi: 10.3233/JAD-160081.

[Research progress in pharmacological effects of Uncaria Hook on Alzheimer disease models]

Liu L, Zhao YH, Zeng CQ, Zeng Y.

Yao Xue Xue Bao. 2016 Apr;51(4):536-42.

Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients

Gauthier S, Rosa-Neto P, Kass JS.

Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):615-8. doi: 10.1212/CON.0000000000000306.

[Alzheimer patients: another approach]

Marrocco J, Hudon J.

Krankenpfl Soins Infirm. 2016;109(3):74-5, 90-1.

Are cognitive interventions effective in Alzheimer's disease? A controlled meta-analysis of the effects of bias

Oltra-Cucarella J, Pérez-Elvira R, Espert R, Sohn McCormick A.

Neuropsychology. 2016 Jul;30(5):631-52. doi: 10.1037/neu0000283. Epub 2016 Apr 7.

Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy

Nabavi SF, Braidy N, Orhan IE, Badiee A, Daglia M, Nabavi SM.

Phytother Res. 2016 Apr;30(4):532-9. doi: 10.1002/ptr.5569. Epub 2016 Jan 11.

sFRP-mediated Wnt sequestration as a potential therapeutic target for Alzheimer's disease

Warrier S, Marimuthu R, Sekhar S, Bhuvanalakshmi G, Arfuso F, Das AK, Bhonde R, Martins R, Dharmarajan A.

Int J Biochem Cell Biol. 2016 Jun;75:104-11. doi: 10.1016/j.biocel.2016.04.002. Epub 2016 Apr 7.

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease

Prati F, Cavalli A, Bolognesi ML.

Molecules. 2016 Apr 8;21(4):466. doi: 10.3390/molecules21040466.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias